Cost per responder of TNF-α therapies in Germany by unknown
BRIEF REPORT
Cost per responder of TNF-α therapies in Germany
Christian Gissel & Holger Repp
Received: 9 April 2013 /Revised: 3 June 2013 /Accepted: 27 June 2013 /Published online: 23 July 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Tumor necrosis factor α (TNF-α) inhibitors
ranked highest in German pharmaceutical expenditure in
2011. Their most important application is the treatment of
rheumatoid arthritis (RA). Our objective is to analyze cost
per responder of TNF-α inhibitors for RA from the German
Statutory Health Insurance funds' perspective. We aim to
conduct the analysis based on randomized comparative ef-
fectiveness studies of the relevant treatments for the German
setting. For inclusion of effectiveness studies, we require
results in terms of response rates as defined by European
League Against Rheumatism (EULAR) or American Col-
lege of Rheumatology (ACR) criteria. We identify conven-
tional triple therapy as the relevant comparator. We calculate
cost per responder based on German direct medical costs.
Direct clinical comparisons could be identified for both
etanercept and infliximab compared to triple therapy. For
infliximab, cost per responder was 216,392 euros for
ACR50 and 432,784 euros for ACR70 responses. For
etanercept, cost per ACR70 responder was 321,527 euros.
Cost was lower for response defined by EULAR criteria, but
data was only available for infliximab. Cost per responder is
overestimated by 40 % due to inclusion of taxes and manda-
tory rebates in German drugs' list prices. Our analysis shows
specific requirements for cost-effectiveness analysis in Ger-
many. Cost per responder for TNF-α treatment in the Ger-
man setting is more than double the cost estimated in a
similar analysis for the USA, which measured against place-
bo. The difference in results shows the critical role of the
correct comparator for a specific setting.
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Introduction
Rheumatoid arthritis (RA) is the most common chronic
inflammatory systemic disease. Its socioeconomic relevance
is characterized by a high prevalence in industrialized coun-
tries combined with the productivity loss associated with the
disease.
The goal of the therapy is early disease control and induc-
tion of sustained remission [1]. Patients can be treated with
conventional or biological disease-modifying therapies.
Methotrexate (MTX) is the most commonly used disease-
modifying antirheumatic drug (DMARD). Tumor necrosis
factor α (TNF-α) inhibitors are the most popular biological
agents approved for the treatment of RA after failure of
conventional DMARDs. Biological agents incur higher di-
rect treatment costs.
Germany is the most populous country in the European
Union and its most important market for biological agents.
The main payer in the German health care system is the
Statutory Health Insurance (SHI). The SHI funds provide
insurance to 90 % of the German population. The SHI funds
have more than 70 million members. With more than EUR 1
billion expenditure, TNF-α inhibitors ranked highest in the
SHI funds' pharmaceutical expenditure in 2011 [2].
For the German population, overall prevalence of inflam-
matory arthritis is estimated at 3.4 % [3]. The prevalence of
RA is 1 %, i.e., approximately 800,000 people [4]. The
percentage of patients treated with TNF-α inhibitors has
been rising from 2 % in 2000 to 20 % in 2008 [5]. In 2011,
adalimumab, etanercept, and infliximab were the most pop-
ular biological agents by sales.
High prevalence and high pharmaceutical spending moti-
vate a cost-effectiveness analysis (CEA) of TNF-α therapies
C. Gissel :H. Repp (*)
Rudolf Buchheim Institute of Pharmacology, Justus Liebig
University Giessen, Schubertstrasse 81, 35392 Giessen, Germany
e-mail: repp@phec.de
C. Gissel
Chair for Industrial Organization, Regulation and Antitrust, Justus
Liebig University Giessen, Giessen, Germany
Clin Rheumatol (2013) 32:1805–1809
DOI 10.1007/s10067-013-2332-1
for the German setting. We aim to conduct a CEA consider-
ing the special requirements for health economic analysis in
Germany.
Methods
We choose cost per responder as the most suitable measure
of cost-effectiveness for the German setting. Quality-
adjusted life years are not used in the German context due
to legal concerns [6]. Cost-effectiveness in terms of cost per
function score unit is problematic as the commonly used
Health Assessment Questionnaire is not cardinally scaled.
We conduct our analysis from the SHI funds' point of
view. Reporting from the main payer's perspective has been
suggested by the Institute for Quality and Efficiency in
Health Care for CEA in Germany.
For inclusion of effectiveness studies, we require results
in terms of response rates as defined either by European
League Against Rheumatism (EULAR) criteria (EULAR
good response, EULAR moderate to good response) or by
American College of Rheumatology (ACR) criteria (ACR50
response, ACR70 response).
First-line biological therapy is not reimbursed by the
German SHI funds unless individual reasons imply poor
response or toxicity of DMARDs. German guidelines re-
quire treatment for at least 6 months and failure of at least
two DMARDs including MTX before the initiation of bio-
logical therapy [7].
While MTX monotherapy is chosen as the comparator
in most CEAs of biological treatments, this would not
reflect German clinical practice. By definition, patients
who are eligible for MTX monotherapy would not be
treated with TNF-α inhibitors in the German setting. Only
MTX refractory patients would be treated with biological
therapies. The German Federal Joint Committee's
(Gemeinsamer Bundesausschuss (GBA)) requirements in-
clude identification of the correct comparator for the spe-
cific patient population [8].
If MTX monotherapy is not effective, DMARD combi-
nation therapy can be initiated as an alternative to biological
treatments [9]. DMARD combination therapy has been
shown to be more effective than MTX monotherapy [10].
We identify conventional triple therapy as the most clinically
relevant alternative to biological therapy as shown by 2011
SHI prescription data [2]. The combination of MTX,
sulfasalazine, and hydroxychloroquine has been shown to
be more effective than MTX monotherapy by O'Dell [11]. It
is the most suitable comparator to reflect a treatment alter-
native to biological therapy in German clinical practice.
Therefore, we search PubMed for clinical comparisons
of TNF-α therapy and triple therapy. We conduct our
analysis based on direct clinical comparisons. Direct
clinical comparisons offer a higher level of evidence than
indirect comparisons according to GBA's requirements [8].
All clinical trials are included if they feature at least one
study arm with biological therapy and one arm with triple
therapy. Initial treatment needs to be MTX monotherapy or
failure of MTX monotherapy has to be an inclusion criterion
for patients.
We search PubMed for the search terms “adalimumab,
sulfasalazine, hydroxychloroquine, and rheumatoid arthri-
tis.” We screen all hits as well as their references for further
studies. The search produced 17 English language results.
One clinical trial could be identified which compared
adalimumab to triple therapy [12]. Application of the same
search terms to infliximab and etanercept produced 40 and
34 hits. Screening of the hits resulted in the identification of
three clinical trials for infliximab [13–17] and two clinical
trials for etanercept [18, 19].
We calculate cost per responder based on German direct
medical costs for the treatments applied in the trials. Cost
calculations include 2013 drug costs and treatment costs
(administration and monitoring cost and screening cost be-
fore initiation of the therapy) according to German SHI
payment conditions.
We report the sensitivity to the national specifics of Ger-
man drug pricing. Contrary to other countries, Germany
applies the full 19 % value-added tax (VAT) to all pharma-
ceuticals. We provide results without VAT for better interna-
tional comparability as shown in Table 1.
In the last decade, the German legislator has routinely
applied mandatory rebates to nonreference price group phar-
maceuticals. The SHI funds' savings due to mandatory re-
bates are not reflected by manufacturers' list prices. The
manufacturers currently have to reimburse the SHI funds
for 16 % of list prices. We report results reflecting the
16 % rebate as shown in Table 1.
Results
Four out of six identified trials were excluded because they
compared combinations of biological and triple therapy rath-
er than comparing biological to triple therapy. The OPERA
study compares adalimumab and MTX combination therapy
plus possible step-up O’Dell triple therapy to MTX (and
adalimumab placebo) therapy plus possible step-up O’Dell
triple therapy [12]. While the placebo arm reflects German
clinical practice, the adalimumab arm includes both biolog-
ical and triple conventional therapy. The NEO-RACo study
added infliximab on top of an existing triple therapy strategy
[15]. O’Dell analyzed the addition of etanercept to either
component of conventional triple therapy [18]. The BeSt
study includes four actively managed study arms (DMARD
sequential monotherapy, DMARD step-up combination
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therapy, DMARD initial combination therapy, initial
infliximab, and MTX combination therapy) [13, 14]. While
providing a valuable comparison of four different treatment
approaches, the active study design ultimately leads to
infliximab combination therapy in all study arms. Each study
arm has an individual treatment plan that differs both in
medication and timing. The study designs are not suitable
to compare biological therapy to conventional therapy for the
purpose of our analysis.
The Swefot trial compares O'Dell's triple therapy to
infliximab and MTX combination therapy after failure of
MTX monotherapy [16, 17]. The Swefot trial reflects two
important characteristics of German practice: failure of MTX
therapy (even though failure of a second DMARD would be
required in Germany) and comparison to O'Dell's triple
treatment.
The Swefot trial reports response rates according to both
ACR criteria and to EULAR criteria. Cost of the study
medication in the German setting is shown in Table 1.
Given the 12 months results of the Swefot trial, the incre-
mental cost-effectiveness ratios (ICER) for ACR response
under infliximab combination therapy compared to O'Dell's
triple therapy are 216,392 euros (ACR50) and 432,784 euros
(ACR70). For EULAR criteria, the ICERs are 154,566 euros
for a good response and 196,720 euros for a good to moder-
ate response (Table 2).
The Treatment of Early Aggressive Rheumatoid Arthritis
(TEAR) trial compares O'Dell's triple therapy to etanercept
and MTX combination therapy, both as initial therapies and
as step-up therapies after the failure of initial MTX
monotherapy after 6 months [19]. Like the Swefot trial, the
two step-up arms reflect the failure of one DMARD. The trial
reports response according to ACR criteria only. After 2
years, only ACR70 response significantly differed between
both study arms. The ICER for a ACR70 response is 321,527
euros (projected for 1 year) (Table 3).
Discussion
A similar analysis for the USA estimated cost per responder
for infliximab at $92,081 by ACR50 criteria and at $152,471
by ACR70 criteria and for etanercept at $63,137 (ACR50)
and at $135,085 (ACR70) against placebo [20]. The costs
estimated in our study are more than twice as high. This
difference can mainly be attributed to the use of triple ther-
apy rather than placebo as a comparator for the German
setting. Our results show that cost per responder would be
underestimated if the relevant comparator was not taken into
account.
However, all German results are overestimated by 40 %
when including VAT and mandatory rebates in the cost
calculations. This needs to be taken into account when
reporting results based on German list prices.
If drug costs are adapted and the specific relevant com-
parator is taken into account, our results can be transferred to
many other countries, which do not use quality-adjusted life
years as part of policy decisions due to legal or political
concerns.
For the Swefot trial, our calculations are based on 12-
month data. However, both trials show little evidence for any
significant clinical advantage of TNF-α therapy after 2 years.
Under the conditions of these trials, TNF-α therapy would
not be cost-effective for MTX refractory patients.
Table 1 Direct costs
Drug costs [€] Administration
and screening
costs [€]





and VAT deducted [€]
Therapy Q1 Qn Q1 Qn Q1 Qn Q1 Qn Q1 Qn Q1 Qn
Triple therapy 175.78 178.95 44.56 44.56 220.34 223.51 192.27 194.94 187.37 190.15 159.31 161.57
IFX + MTX 8,387.80 4,555.97 247.80 75.52 8,635.60 4,631.49 7,296.37 3,904.07 7,536.22 4,031.78 6,197.00 3,304.36
ETN + MTX 5,691.38 5,694.55 201.00 57.35 5,892.38 5,751.90 4,983.67 4,842.69 5,154.79 5,013.92 4,246.09 4,104.70
IFX infliximab, ETN etanercept, MTX methotrexate, Q1 first quarter of treatment, Qn following quarters of treatment
Table 2 Cost per responder for infliximab combination therapy compared to conventional triple therapy
Response ACR20 ACR50 ACR70 EULAR (Good) EULAR (Moderate–good)
Cost per responder [€] 154,566 216,392 432,784 154,566 196,720
Cost per responder, VAT deducted [€] 130,225 182,315 364,629 130,225 165,741
Cost per responder, rebates deducted [€] 134,813 188,738 377,475 134,813 171,580
Cost per responder, VAT and rebates deducted [€] 110,472 154,660 309,321 110,472 140,600
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Current EULAR recommendations do not explicitly rec-
ommend conventional DMARD combination therapy [21].
A more prominent role of conventional combination therapy
could contribute to significant direct medical cost savings.
At 5 years, the BeSt study has shown that 19 % of patients
are in drug-free remission after initial treatment with infliximab
[22]. Comparable rates might be achieved even if not applied as
first-line therapy. The possibility for drug-free remission could
have an important impact on the results of CEA.
Accounting for prevented disability in long-term analysis
can substantially change the results of CEA if conducted
from a societal perspective. Initial biological therapy with
adalimumab showed an advantage in radiographic progres-
sion over MTX monotherapy even if adalimumab therapy
was discontinued after 1 year [23].
Limitations
If no response could be achieved, the Swefot trial allowed
switching the therapy from infliximab to etanercept and from
triple therapy to cyclosporin A. These adjustments are not
reflected by our cost calculations. However, the variations in
costs do not alter our conclusions. The huge cost difference
between biological and conventional therapy does not sig-
nificantly change for either switch.
The data discovered to directly base CEA upon is very
limited. The Swefot trial only includes 258 patients over the
course of 2 years. The setup of the trial does not fully reflect
German guidelines. The same critique applies to CEA based
on the TEAR trial with 379 patients in the step-up arms.
Conclusions
Our analysis has shown specific requirements for CEA for
the German market. CEA by cost per responder is a viable
option for jurisdictions, which do not use quality-adjusted
life years. Our results reflect GBA's requirements for rele-
vant comparators as currently practiced in its early benefit
assessments for new approvals in Germany [8].
While our analysis focused on the agents with the
highest budget impact in 2011, GBA selected tocilizumab,
golimumab, and certolizumab pegol for the first benefit as-
sessment of biological agents for RA in 2014 [24]. These
agents are in an earlier stage of their product lifecycle. Due
to their expected future budget impact, their manufacturers are
required to negotiate a rebate with the SHI funds based on
GBA's benefit assessment. Our analysis has shown that the
choice of the comparator will play a critical role.
Cost per responder for the German setting is more than
double the cost estimated in a similar analysis for the USA,
which measured against placebo. However, German results
are overestimated by 40 % when calculating based on the
drugs' list prices.
Conclusions need to be drawn with caution. Recent re-
search has shown the possibilities of long-term drug-free
remission and improved radiographic progression with early
biological treatment. Further research is required to deter-
mine the long-term cost-effectiveness of biological ap-
proaches to treatment of RA.
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